Back to Shop
KPV Peptide
Anti-Inflammatory

KPV

KPV peptide with potent anti-inflammatory properties.

Dosage
  • Dosage 10mg
  • Volume 2ml

$89.99

Add to Cart
Product Care

Store in a cool, dry place away from light. If Constituted, Please Refrigerate. For longer term storage, freezing at -20°C is recommended to maintain integrity.

Product Note

All products are shipped in lyophilized or powder form and must be reconstituted to a liquid for research and testing. We are unable to provide any dosing instructions. All peptides are for research use only. We're an expert biotechnology company that provides high quality peptides and products for purchase to advance scientific research in this field.

Long-Acting Growth Factor

IGF-1 LR3 — Research & Data

A modified form of insulin-like growth factor 1 with an extended half-life due to an arginine substitution at position 3 and a 13-amino-acid extension. IGF-1 LR3 has reduced IGF binding protein affinity, increasing bioavailability.

20-30 hrs

Half-Life

vs 12-15 min native IGF-1

Reduced

IGFBP Binding

Higher free fraction

Anabolic

Signaling

Muscle & tissue growth

PI3K/Akt

Pathway

Cell survival & growth

How IGF-1 LR3 Works

IGF-1 LR3 binds the IGF-1 receptor (IGF-1R) with similar affinity to native IGF-1, activating PI3K/Akt and MAPK/ERK signaling cascades. The Arg3 substitution and N-terminal extension reduce affinity for IGF binding proteins (IGFBPs), meaning more of the molecule remains free and bioactive rather than sequestered. This results in 2-3x greater potency and 20-30 hour half-life vs native IGF-1's 12-15 minutes.

Mechanisms of Action
IGF-1R Activation

Binds IGF-1 receptor to activate PI3K/Akt and MAPK/ERK pathways, promoting cell proliferation and survival.

Reduced IGFBP Affinity

Arg3 substitution decreases binding to IGF binding proteins, resulting in higher bioavailable IGF-1 activity.

Anabolic Effects

Promotes skeletal muscle hypertrophy, satellite cell proliferation, and nitrogen retention in preclinical models.

What Research Has Shown

Preclinical studies show IGF-1 overexpression produces significant muscle hypertrophy and strength gains. The LR3 modification extends half-life from minutes to 20-30 hours with 2-3x greater in vitro potency. IGF-1 signaling is critical for muscle, bone, and CNS development. Human clinical data for LR3 specifically is limited; most human data comes from recombinant IGF-1 (mecasermin).

Research Areas
Muscle Research

IGF-1 LR3 shows coordinate effects on both protein synthesis and breakdown in catabolic models.

Protein synthesis Increased
Protein breakdown 3x reduction
Nitrogen retention Enhanced
Tissue Growth

IGF-1 LR3 demonstrates pronounced effects on visceral organ growth, particularly the GI tract.

Gut weight increase +45%
Spleen weight +35%
Kidney weight +30%
Neuroprotection

Intranasal IGF-1 LR3 has been studied for its potential to delay cognitive decline in animal models.

Research status Active area
Catabolic Reversal

IGF-1 LR3 reversed glucocorticoid-induced catabolism with 2.5x potency vs native IGF-1.

Weight recovery +6g vs -19g control
Potency advantage 2.5x
Clinical Outcomes

2.5x

Anabolic potency vs IGF-1

Anti-catabolic effects

20-30 hrs

Half-life extension

vs 12-15 min native

~10%

IGFBP binding

Increased free fraction

Regulatory Status
WADA Prohibited Substance (S2 category)
Not approved by FDA for any indication
No regulatory approval in any jurisdiction
Research compound only
Dosing Information from Research

Research protocols use 20–100 μg/day subcutaneously or intramuscularly. Some protocols use localized intramuscular injection at the target site. Typical research duration: 4-6 weeks with monitoring. Due to its high potency, precise dosing is critical.

Pharmacokinetics

Half-life: 20-30 hours (vs 12-15 minutes for native IGF-1). Peak plasma levels occur 1-2 hours after subcutaneous injection. Steady-state is achieved within 2-3 days of daily dosing. Reduced IGFBP binding means higher free fraction and greater tissue exposure.

How It Works in the Body

IGF-1 LR3 binds IGF-1R on cell surfaces, causing receptor autophosphorylation. This activates IRS-1 → PI3K → Akt cascade (promoting protein synthesis, glucose uptake, and cell survival) and Ras → MAPK/ERK cascade (promoting cell proliferation). In muscle, this stimulates satellite cell activation, myoblast proliferation, and protein synthesis. The reduced IGFBP binding means more of the molecule reaches target tissues in active form.

Important Notes
  • IGF-1 LR3 is 2-3x more potent than native IGF-1 due to reduced IGFBP sequestration.
  • It can cause dose-dependent hypoglycemia — glucose monitoring is essential in research protocols.
  • Native IGF-1 (mecasermin/Increlex®) is FDA-approved for severe IGF-1 deficiency; LR3 is a research compound.
  • IGF-1 signaling is implicated in both growth/repair AND cancer biology — use with appropriate precautions.
Safety Profile from Research
What clinical studies report

Limited human safety data specific to LR3. Native IGF-1 (mecasermin) safety data shows hypoglycemia as the most significant risk. Other reported effects include headache, injection site reactions, and jaw pain. Long-term IGF-1 elevation may carry theoretical oncogenic risk.

Common Digestive Issues

Not a primary concern. Nausea reported in <5% of native IGF-1 users.

Theoretical Concern — Hypoglycemia Risk

IGF-1 LR3 enhances glucose uptake and can cause dose-dependent hypoglycemia. Blood glucose monitoring is essential. Symptoms include tremor, sweating, confusion, and in severe cases, loss of consciousness.

Theoretical Concern — Oncogenic Potential

Sustained IGF-1R activation promotes cell proliferation and inhibits apoptosis. Epidemiological data links elevated IGF-1 levels with increased cancer risk. Research protocols should include appropriate monitoring.

Treatment Discontinuation Rates

Not well-established for LR3. Native IGF-1 trials report 5-10% discontinuation, primarily due to hypoglycemia.

Study Exclusion Criteria

Active or history of malignancy, diabetes requiring insulin, known hypoglycemia disorders, children with closed growth plates.

Researcher Notes
  • Always have glucose available when administering IGF-1 LR3 in research protocols.
  • Combine with food intake to mitigate hypoglycemia risk.
  • IGF-1 LR3 is one of the most potent anabolic research peptides — start with conservative doses.
  • Monitor blood glucose, IGF-1 levels, and general metabolic panels during research.
Compound Information
Molecular Weight 9,111 g/mol
Sequence 83 amino acids (13 aa N-terminal extension + Arg3 substitution of native IGF-1)
Formula C400H625N111O115S9
CAS Number 946870-92-4
Purity ≥95%
Form Lyophilized powder (white)
Storage Requirements
Lyophilized

Store at -20°C. Very sensitive to temperature fluctuations.

Reconstituted

Use within 7 days at 2-8°C. Add 0.1% BSA or acetic acid to prevent adsorption.

Light Sensitivity

Moderate. Store in opaque containers.

Research Status — Where It Stands

IGF-1 LR3 is widely used in cell biology and preclinical research. Native IGF-1 (mecasermin) is FDA-approved for severe IGF-1 deficiency. LR3 is a research-use-only compound with no regulatory approval.

Published Studies
Muscle Hypertrophy Study
2005

IGF-1 overexpression in muscle tissue produced significant hypertrophy and strength gains in animal models.

Extended Bioactivity
2002

LR3 modification extended IGF-1 half-life from minutes to 20-30 hours with 3x greater potency in vitro.

IGF-I variants are anabolic in dexamethasone-treated rats
1992

IGF-1 LR3 was 2.5-fold more potent than native IGF-1 in reversing catabolic state.

Superior potency of infused IGF-I analogues
1996

IGF-1 LR3 maintained superior potency when administered by injection vs infusion.

IGF-binding proteins are multifunctional
2002

Detailed mechanism of how IGFBP evasion enhances LR3 bioavailability.

Frequently Asked Questions

IGF-1 LR3 is a synthetic analogue of human IGF-1. It differs from native IGF-1 by having a substitution of Glutamine for Arginine at position 3, and a 13-amino acid extension at the N-terminus. This makes it 2-3 times more potent and significantly extends its half-life.

Yes, like native IGF-1, IGF-1 LR3 can enhance glucose uptake and potentially lead to hypoglycemia. Blood glucose monitoring is essential in research protocols involving this compound.

Sources & References
Barton et al. — Muscle-Specific IGF-1 Expression and Hypertrophy (2005) Francis et al. — LR3 IGF-1 Extended Bioactivity (2002) Increlex® (mecasermin) Prescribing Information